Business Context and Reporting Period
This Form 8-K, dated December 11, 2025, reports on shareholder actions taken by Indivior PLC to facilitate a Scheme of Arrangement. The filing details the approval of amended articles of association and the results of two shareholder meetings held on December 11, 2025, aimed at restructuring the company into Indivior Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and structural changes rather than financial performance.
Material Changes and Shareholder Votes
Shareholders approved a Scheme of Arrangement to restructure the company. Key voting results include:
- Court Meeting: The Scheme of Arrangement was approved with 94,968,161 votes for and 46,544 votes against.
- Extraordinary General Meeting: Shareholders passed six special resolutions, including authorizing the reduction of share capital, the issuance of new shares, and the re-registration of the company as a private entity.
- Amended Articles: A new Article 136 was introduced to ensure all shares issued prior to the Scheme Record Time are bound by the Scheme terms.
Outlook, Risks, and Contingencies
The completion of the Scheme of Arrangement is contingent upon the sanction of the High Court of Justice in England and Wales. A hearing for this sanction is expected on January 22, 2026, with the Scheme expected to complete later in January 2026. Upon completion, Indivior PLC will become a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc.
Investor Verification Checklist
- Confirm the date and outcome of the High Court of Justice hearing scheduled for January 22, 2026.
- Verify the final completion date of the Scheme of Arrangement and the subsequent delisting of Indivior PLC from Nasdaq.
- Review the full text of the Amended and Restated Articles of Association (Exhibit 3.1) for specific terms regarding share conversion.
- Monitor for the issuance of new Indivior Pharmaceuticals, Inc. shares to existing Indivior PLC shareholders.